Oracle International Corporation

Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Ying Hu

Siva Ravada

Seema Sundara

Jagannathan Srinivasan

Richard James Anderson, Jr

Carmelo Romano

Adrianna Latuszek

Alexander O Mujica

Andrew J Murphy

Stanley J Wiegand

Jingtai Cao

Susan D Croll

Min Gao

Bhuvan Bamba

Lynn Macdonald

William C Olson

Timothy Chorma

Nipun Agarwal

Zhen Hua Liu

Shasank Kisan Chavan

Aris I Baras

Vikas Arora

Yajun Tang

Jeffrey D Lee

Goncalo Abecasis

Kavita Praveen

John R McWhirter

Karolina Meagher

Giovanni Coppola

Daniel Geringer

Gaurang Patel

Douglas James McMahon

Beda Christoph Hammerschmidt

Souripriya Das

Dinesh Das

Sriram Krishnamurthy

Aurosish Mishra

Eugene Inseok Chong

Chandrasekharan Iyer

Wesley Lin

Lauren Gurski

Tanya Teslovich Dostal

Claudia Schurmann

John Mcwhirter

William Martinez Cortes

Beethoven Cheng

Giusy Della Gatta

Trikaldarshi Persaud

Ming Yuan

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

Mouse comprising a humanized TRKB locus

The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

Anti-TrkB monoclonal antibodies and methods of use

The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

Described is a system, method, and computer program product to perform bi-directional mapping of hierarchical data (e.g. JSON, XML) to database object types (e.g., user defined database object types).

Bidirectional mapping of hierarchical data to database object types

Techniques are introduced herein for maintaining geometry-type data on persistent storage and in memory. Specifically, a DBMS that maintains a database table, which includes at least one column storing spatial data objects (SDOs), also maintains metadata for the database table that includes definition data for one or more virtual columns of the table. According to an embodiment, the definition data includes one or more expressions that calculate minimum bounding box values for SDOs stored in the geometry-type column in the table. The one or more expressions in the metadata maintained for the table are used to create one or more in-memory columns that materialize the bounding box data for the represented SDOs. When a query that uses spatial-type operators to perform spatial filtering over data in the geometry-type column is received, the DBMS replaces the spatial-type operators with operators that operate over the scalar bounding box information materialized in memory.

Techniques for in-memory spatial object filtering

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

Polynucleotides encoding anti-C5 antibodies

Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

[object Object]

Techniques described herein perform spherical PIP analysis by detecting whether a test ray (defined by a test point (TP) and a point (EP) that is external to a spherical polygon) crosses edge arcs ('edges') of the polygon based on relative orientations of vertices of the test ray and edges. A classifier vector (CV) for a test ray is calculated based on the cross-product of the TP and the EP. Using the CV, the orientation of each vertex of the polygon with respect to the test ray is determined. Candidate edges having vertices with opposite orientations with respect to the test ray are identified. Crossing edges are determine by calculating CVs for each candidate edge, and determining orientations of the TP and EP with respect to each candidate edge. A set of crossing edges is determined, where the TP and the EP have opposite orientations with respect to each crossing edge.

Techniques for solving the spherical point-in-polygon problem

Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

Humanized C5 animals

Anti-C5 antibodies

Humanized C3 animals

Growing community of inventors

Nashua, NH, United States of America

Ying Hu